Potential MS therapy improves myelin repair in cells and mice - Multiple Sclerosis News Today

What the report says

Multiple Sclerosis News Today reported on July 28, 2026, that an experimental small molecule known as CN045 improved several measures linked to myelin repair in preclinical research. The compound encouraged immature oligodendrocyte progenitor cells to become mature oligodendrocytes, the cells that produce myelin, in laboratory studies. It also produced a modest increase in remyelination in a mouse model of myelin loss.

The findings came from a study titled “A novel small molecule remyelination therapy for multiple sclerosis,” published in npj Drug Discovery. According to the report, researchers in the U.S. screened 20,000 molecules selected for properties that could be useful in the central nervous system, with CN045 emerging as the lead candidate. In tests using human progenitor cells, CN045 increased mature myelin-producing cells, and those cells formed myelin-like sheaths around artificial nanofibers designed to resemble nerve fibers.

The article noted that current disease-modifying therapies for multiple sclerosis can reduce inflammatory attacks, relapses and new lesions, but they do not directly rebuild damaged myelin. Because myelin helps nerve signals move efficiently through the brain and spinal cord, a therapy that restores it could potentially help protect nerve fibers and preserve function, though that remains unproven for CN045.

Multiple Sclerosis News Today said the compound showed some favorable early drug-development traits, including brain penetration and low toxicity in laboratory and animal testing. However, CN045 was also reported to break down quickly in the body, meaning further chemical optimization and additional research would be needed before any consideration of human testing. The work was supported by the National Institutes of Health, the National Multiple Sclerosis Society and Ohio Fast Forward.